Arrivent Biopharma Inc (AVBP) Stock Price, Quote & News

Company Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment o...

Industry: Biotechnology

Sector: Healthcare

Phone: 628 277 4836

Website: arrivent.com

Address:

18 Campus Boulevard, Suite 100, Newtown Square, United States

Smellmahass Apr. 9 at 9:29 AM

$AVBP When did they delay data and why?

2 · Reply

baliosxantos Apr. 8 at 9:07 PM

$AVBP

0 · Reply

SuperGreenToday Apr. 8 at 6:44 PM

$AVBP Share Price: $25.08 Contract Selected: Oct 16, 2026 $25 Calls Buy Zone: $8.50 – $10.50 Target Zone: $14.75 – $18.03 Potential Upside: 64% ROI Time to Expiration: 190 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

laaarsas Apr. 6 at 8:17 PM

$AVBP I'm starting to lean more towards that firmonertinib might perform closer to sunvozertinib rather than mobocertinib. If that is true, we could see some nice data in a few months. What are your thoughts?

0 · Reply

laaarsas Apr. 6 at 2:57 PM

$AVBP What is the effect size of WU-KONG28?? They only say positive? We must know this!

0 · Reply

laaarsas Apr. 6 at 2:37 PM

$AVBP Yes, we already have class failure from mobocertinib. How can this be salvaged? I don't see it happening.

0 · Reply

laaarsas Apr. 6 at 1:46 PM

$AVBP A huge warning sign is that class-relative mobocertinib failed on PFS vs same control in EXCLAIM-2. Why should Arrivent do any better?

0 · Reply

laaarsas Apr. 6 at 12:28 PM

$AVBP If they replicate results from amivantanab and the PAPILLON, would that be a clear win for the company? A significant jump i share price?

0 · Reply

laaarsas Apr. 6 at 12:09 PM

$AVBP This seems highly interesting so far. Reading up. Hit me with all the negatives. What is the bear case? All risks. Hit me!!

0 · Reply

laaarsas Apr. 6 at 11:01 AM

$AVBP Yo cats what's up?

0 · Reply

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Mar 5, 2026, 4:01 PM EST - 5 weeks ago

ArriVent BioPharma Reports Full Year 2025 Financial Results

Dec 22, 2025, 8:00 AM EST - 4 months ago

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Nov 10, 2025, 8:00 AM EST - 5 months ago

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

Sep 22, 2025, 4:05 PM EDT - 7 months ago

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Sep 9, 2025, 8:00 AM EDT - 7 months ago

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

Aug 11, 2025, 8:00 AM EDT - 8 months ago

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Jul 21, 2025, 8:00 AM EDT - 9 months ago

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Jul 2, 2025, 8:22 AM EDT - 10 months ago

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

BV CNC

Jul 1, 2025, 11:15 PM EDT - 10 months ago

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 4:05 PM EDT - 10 months ago

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jun 23, 2025, 7:00 AM EDT - 10 months ago

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

Jun 20, 2025, 4:05 PM EDT - 10 months ago

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Reports First Quarter 2025 Financial Results

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Reports Full Year 2024 Financial Results

Jan 21, 2025, 7:00 PM EST - 1 year ago

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Sep 9, 2024, 12:05 PM EDT - 1 year ago

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Aug 15, 2024, 7:01 AM EDT - 1 year ago

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

Aug 14, 2024, 4:01 PM EDT - 1 year ago

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 8:00 AM EDT - 1 year ago

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

Jun 5, 2024, 7:00 AM EDT - 2 years ago

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

May 16, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

May 8, 2024, 8:00 AM EDT - 2 years ago

ArriVent BioPharma Reports First Quarter 2024 Financial Results

Apr 22, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints Kristine Peterson to its Board of Directors

Mar 28, 2024, 8:30 PM EDT - 2 years ago

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ArriVent BioPharma Reports Full Year 2023 Financial Results

Smellmahass Apr. 9 at 9:29 AM

$AVBP When did they delay data and why?

2 · Reply

baliosxantos Apr. 8 at 9:07 PM

$AVBP

0 · Reply

SuperGreenToday Apr. 8 at 6:44 PM

0 · Reply

laaarsas Apr. 6 at 8:17 PM

0 · Reply

laaarsas Apr. 6 at 2:57 PM

$AVBP What is the effect size of WU-KONG28?? They only say positive? We must know this!

0 · Reply

laaarsas Apr. 6 at 2:37 PM

$AVBP Yes, we already have class failure from mobocertinib. How can this be salvaged? I don't see it happening.

0 · Reply

laaarsas Apr. 6 at 1:46 PM

$AVBP A huge warning sign is that class-relative mobocertinib failed on PFS vs same control in EXCLAIM-2. Why should Arrivent do any better?

0 · Reply

laaarsas Apr. 6 at 12:28 PM

$AVBP If they replicate results from amivantanab and the PAPILLON, would that be a clear win for the company? A significant jump i share price?

0 · Reply

laaarsas Apr. 6 at 12:09 PM

$AVBP This seems highly interesting so far. Reading up. Hit me with all the negatives. What is the bear case? All risks. Hit me!!

0 · Reply

laaarsas Apr. 6 at 11:01 AM

$AVBP Yo cats what's up?

0 · Reply

SuperGreenToday Apr. 1 at 6:38 AM

$AVBP Share Price: $23.07 Contract Selected: Oct 16, 2026 $25 Calls Buy Zone: $6.50 – $8.03 Target Zone: $12.35 – $15.10 Potential Upside: 79% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

erevnon Mar. 23 at 4:14 PM

B. Riley Securities maintains ArriVent BioPharma $AVBP at Buy and raises the price target from $37 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

OfficialStocktwitsUser Mar. 16 at 4:29 PM

$AVBP RSI: 56.38, MACD: 0.5568 Vol: 1.00, MA20: 23.91, MA50: 22.64 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

STACKD0E Mar. 9 at 2:43 PM

$AVBP $OMDA $RDNW $AVXL 🙃✨

0 · Reply

elmono Mar. 6 at 10:01 AM

$AVBP event driven data delayed to mid 2026 is likely a positive for trial outcome….. if anything the balance of probabilities should cause the sp to rise …..

2 · Reply

Eagley3k Mar. 6 at 1:02 AM

$AVBP data delayed to mid 2026?

2 · Reply

justiceforb_85 Mar. 5 at 2:17 AM

$AVBP impressive movement.

0 · Reply

judgeyoung2 Mar. 4 at 6:11 PM

$AVBP i guess i’ll strangle it. if no data comes by tomorrow, i’ll dip.

0 · Reply

judgeyoung2 Mar. 4 at 4:17 PM

$AVBP @cubie @tonyctl anything interesting on the flow?

1 · Reply

Zawang Mar. 4 at 3:54 PM

$AVBP why is this up so much today? I can’t find any news.

0 · Reply

Eagley3k Mar. 4 at 3:32 PM

$AVBP Took a position today.

0 · Reply

QuantInsider Feb. 28 at 4:11 PM

$AVBP had a quiet week No big news, just a single OTM call sweep caught my eye 155 contracts of Mar 20 $35 calls, 47% OTM, bought at the ask for about $49.6K Looks like a speculative play, not a big bullish move Implied volatility on that call is around 246%, so options are pricey Watch out for decay unless a big move happens soon This feels more like a watchlist anomaly than a setup No strong signals here, just keeping an eye on it

0 · Reply

Market Cap	1.18B
Revenue (ttm)	0.00
Net Income (ttm)	-166.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	594,400
Avg Vol	537,628
Day's Range	N/A - N/A
Shares Out	44.20M
Stochastic %K	96%
Beta	0.85
Analysts	Strong Sell
Price Target	$42.92